Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial

AETHLON MEDICAL INC

2025-Q2 EPS reported -$0.50 vs consensus -$8.77 ▲ beat (+94.3%)

Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.
Enrolled first two patients in safety/feasibility Hemopurifier trial for solid tumors at Royal Adelaide Hospital.
Two Australian sites open; third site ethics approval pending; India site approved at Medanta Medicity.
James Frakes permanently appointed CEO, previously interim since Nov 2023.
Operating expenses decreased 9% to $2.9M due to cost-cutting and legal fee reductions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.